Overview of the applications for the conditional entry into the Basic Insurance Package by ZIN

10

Sep 2019

At the beginning of August 2019, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) has published an overview of the procedures for the conditional entry into the Basic Insurance Package – the instrument introduced by the Minister of Health, Welfare, and Sport (Volksgezondheid, Welzijn en Sport, VWS). Conditional entry applies to new and existing forms of health care, whereby the condition is that data must be collected on effectiveness and cost-effectiveness. These data can eventually be used to decide on permanent entry into the package, termination of the – conditional – entry, or advising the Minister on removal from the package.

The process consists of the following phases:

  • Phase 0 – The opportunity to submit a dossier for the conditional admission
  • Phase 1 – The assessment of the dossier by ZIN and the Dutch Organisation for Health Research and Development (De Nederlandse organisatie voor gezondheidsonderzoek en zorginnovatie, ZonMw). The preliminary approval is not given by the Ministry of Health, Welfare and Sport (Ministerie van Volksgezondheid, Welzijn en Sport, VWS) yet
  • Phase 2 – The agreement development process is initiated; the assessment of the agreement by ZIN is conducted. The request for final approval is sent to VWS
  • Phase 3 – Start of the main effectiveness and cost-effectiveness study for the conditionally authorized intervention, that approximately lasts about 3.5 years
  • Phase 4 - Before the end of the conditional entry process, ZIN decides whether the intervention meets 'the state of science and practice' or not. Based on this, further information regarding its inclusion into the basic package is provided

Finally, the forms of health care included in the Basic Insurance Package in a framework of the conditional are reimbursed for a certain period in the basic package.

The applications for procedures and medical devices are in the following phases:

  • Heated intraperitoneal chemotherapy (HIPEC) added to primary debulking surgery in patients with stage III ovarian cancer is in phase 2
  • GAG therapy in patients with bladder pain syndrome (BPD) with Hunnian lesions is in phase 1

The overview is available in Dutch here.

Find the details about the scheme in Dutch here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

25

Mar 2022

On March 4, 2022, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) announced three projects which received a subsidy under the "Subsidy scheme for promising care" in 2022 for research of a new minimally invasive endoscopy-guided surgery in patients with spontaneous cerebral hemorrhage, oral immunotherapy in children to cure a food allergy and cutting the diaphragm band in chronic abdominal complaints.

Read more

18

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Read more

17

Mar 2022

On February 21, 2022, it was announced by the Ministry of Health that the public consultation regarding the Draft Order amending the Common Package of Benefits of the National Health System (SNS) was open. The amendments and clarifications are related to the fields of in-vitro diagnostics, ENT, pulmonary and airways, e-health, neurology, dental care, radiology, and enteral nutrition.

Read more

14

Mar 2022

In February 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, published Bulletins 0182 and 0079 with changes to be implemented no later than April 10, 2022. Three new procedure codes concerned robotic surgery in orthopaedic area, spinal procedures, and ophthalmology, and five new diagnostic codes were introduced.

Read more

08

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.

Read more